SCHEMBL4381371

SCHEMBL4381371

Cc1csc2c(Oc3ccc4nc(NC(=O)Cc5ccccc5)sc4c3)ncnc12

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.55
CSNK1D P48730 10/20 0.53
ROCK2 O75116 2/20 0.51
WNT3A P56704 4/20 0.51
MEN1 O00255 2/20 0.51
ALDH1A1 P00352 2/20 0.51
KMT2A Q03164 2/20 0.51
HSD17B10 Q99714 1/20 0.51
RAB9A P51151 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
NPC1 O15118 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50
BLM P54132 1/20 0.50
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4382502 0.84 MET (0.56) METCSNK1DROCK2WNT3AMEN1
SCHEMBL4371744 0.79 MET (0.77) METCSNK1DROCK2WNT3A
SCHEMBL4374930 0.78 MET (0.57) METCSNK1DROCK2WNT3AMEN1
SCHEMBL4376852 0.78 WNT3A (0.68) METCSNK1DWNT3AMEN1ALDH1A1
SCHEMBL4914800 0.77 CSNK1D (0.87) CSNK1DWNT3AMEN1ALDH1A1KMT2A
SCHEMBL4373886 0.74 CSNK1D (0.64) METCSNK1DROCK2WNT3ACYP3A4
SCHEMBL14189668 0.73 CSNK1D (0.77) CSNK1DMEN1ALDH1A1KMT2AHSD17B10
SCHEMBL4373367 0.73 MET (0.79) METCSNK1DWNT3AMEN1ALDH1A1
SCHEMBL5180187 0.72 MET (0.63) METCSNK1DROCK2WNT3AMEN1
SCHEMBL371580 0.71 MET (1.00) METCSNK1DWNT3ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 US disclosed
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 US disclosed
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 US disclosed
US-20050245547-A1 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma AMGEN INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245547-A1 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma HGF, MET, HGFAC MET 2/4885CSNK1D 1568/4885ROCK2 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.